MedTrace Logo

Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)

NCT03366207 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2019-09-06

Study results available
· View outcomes & findings →

Summary

This is a prospective, Phase 4, open label, multi-center study of the clinical and microbiologic efficacy of ciprofloxacin for the treatment of uncomplicated urinary tract infections in adult women.

Conditions

  • UTI - Lower Urinary Tract Infection
  • Antibiotic Resistant Infection

Interventions

DRUG

Ciprofloxacin

Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.

Sponsors & Collaborators

  • Iterum Therapeutics, International Limited

    lead INDUSTRY

Principal Investigators

  • Steven Aronin, MD · Iterum Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2018-07-31
Completion
2018-10-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03366207 on ClinicalTrials.gov